This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.

Inclusion Criteria

Cohort 1 Participants:

• Age ≥ 45 years, OR age ≥ 18 years with at least one risk factor
• Diagnosed with abnormal uterine bleeding (AUB)
• Planning standard-of-care endometrial tissue sampling to assess for endometrial cancer (EC) or atypical endometrial hyperplasia/endometrial intraepithelial neoplasia (AEH/EIN)

Cohort 2 Participants:

• Age ≥ 18 years
• Newly diagnosed, biopsy-confirmed EC or AEH/EIN
• Planning initial management for their endometrial pathology

Exclusion Criteria

• Prior partial or complete hysterectomy
• Current pregnancy
• Prior pelvic or vaginal radiotherapy
• Chemotherapy within past 5 years (except tamoxifen)
• Any condition judged by the Investigator to preclude participation

Additional for Cohort 1:

• Cancer diagnosis within past 5 years (except non-gynecologic skin cancer)
• Current biopsy-proven cervical, vaginal, or vulvar cancer, or lower genital tract dysplasia
• Current biopsy-proven endometrial cancer, hyperplasia, or benign polyp
• Benign endometrial biopsy within last month

Additional for Cohort 2:

• Cancer diagnosis other than EC within past 5 years (except non-gynecologic skin cancer)
• Prior cervical cancer or biopsy-proven cervical dysplasia
• Surgery for recurrent EC
• Preoperative neoadjuvant chemotherapy or radiotherapy for current EC
• Prior treatment or surgery to remove target pathology during current episode

Patients receiving routine clinical care within participating primary care, gynecology, oncology, and Veterans Affairs health systems across rural, urban, and suburban regions of the United States.

Individual participant data that underlie the results reported in publications of the study will be shared after deidentification. This may include test, tables, figures, and appendices. The study protocol, statistical analysis plan (when applicable), informed consent form (when applicable), and the clinical study report (when applicable) will also be shared.

Data will be available from 2 years and ending 4 years after publication.

Proposals for access to data should be directed to clinicaltrials@exactsciences.com. To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement. Researchers are required to obtain necessary IRB/IEC approvals or waivers as applicable to conduct research